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Abstract: As the leading cause of cancer death worldwide, lung can-
cer continues to impose a major burden on healthcare systems and 
cause significant challenges for clinicians and patients. Most patients 
present with advanced disease at the time of diagnosis and have a 
poor prognosis, with the vast majority surviving less than 5 years. 
Although new therapies have been introduced in recent years that tar-
get molecular disease drivers present in a subset of patients, there is 
a significant need for treatments able to improve response and extend 
survival while minimizing effects on quality of life. Recent evidence 
of clinical efficacy for immunotherapeutic approaches for lung cancer 
suggests that they will become the next major therapeutic advance for 
this disease. Non–small-cell lung cancer, which accounts for approxi-
mately 85% of lung cancer cases, has historically been considered a 
nonimmunogenic disease; however, as with several other malignan-
cies, recent data show that much of this lack of immune responsive-
ness is functional rather than structural (i.e., possible to overcome 
therapeutically). This review explores the key elements of the immune 
system involved in non–small-cell lung cancer and briefly examines 
immunotherapeutic strategies in development to shift the balance of 
immune activity away from a tumor-induced immune-suppressive 
state toward an active antitumor immune response.
Key Words: Non–small-cell lung cancer, Immune system, 
Immunotherapy, Checkpoint inhibitors, Cancer vaccines.
(J Thorac Oncol. 2015;10: 974–984)
Lung cancer is the leading cause of cancer-related death worldwide, claiming an estimated 1.59 million lives in 
2012.1 Non–small-cell lung cancer (NSCLC) is the pre-
dominant form of the disease, accounting for approximately 
85% of cases.2 The majority of patients present with locally 
advanced or metastatic disease, and many do not survive more 
than 5 years beyond diagnosis.2,3 Although targeted therapy 
has produced real benefit for specific molecular subtypes of 
NSCLC, traditional chemotherapy, which usually provides 
short-lived benefit, remains the only option for most patients. 
Consequently, there remains a major need for therapy that 
significantly extends patient survival without compromising 
quality of life.
In recent years, there has been an increasing recogni-
tion of the role of the immune system in cancer development 
and progression,4–6 with a corresponding focus on utiliz-
ing immunotherapy in the clinic and regulatory approvals of 
immunotherapy for renal cell cancer (interleukin [IL]-2 and 
interferon-α7), prostate cancer (sipuleucel-T8), and melanoma 
(ipilimumab,9 nivolumab,10 pembrolizumab11). Although 
NSCLC has historically been considered a nonimmunogenic 
disease, emerging evidence has demonstrated that the lack 
of an effective immune response is in fact often the result of 
specific, active immune-evasive mechanisms, which if under-
stood can be overcome therapeutically with significant clinical 
efficacy. Harnessing this potential has therefore become a pri-
mary area of clinical interest.12–14 Given the increasing under-
standing of the role of immunology in oncology, this article 
examines the key elements of the immune system involved 
in cancer in general and in NSCLC specifically, and briefly 
outlines some of the immunotherapeutic strategies currently 
being developed to improve patient outcomes.
THE IMMUNE SYSTEM AND CANCER
The Antitumor Immune Response
The immune system is now recognized to have the poten-
tial to destroy cancer cells and inhibit tumor growth through 
responses elicited by its innate and adaptive arms.15 Innate 
immune responses are antigen nonspecific, develop quickly, 
and are mediated by various effector cells (natural killer [NK] 
cells, polymorphonuclear leukocytes, and mast cells, as well 
as antigen-presenting cells (APGs), such as macrophages and 
dendritic cells [DCs]), which lead to the secretion of inter-
feron gamma (IFN-γ) and perforin, as well as inflammatory 
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cytokines that induce apoptosis of tumor cells.4 In contrast, 
adaptive immune responses are antigen specific, develop more 
slowly, offer immune memory, and comprise both humoral and 
cellular immunity mediated by B and T cells, respectively.15,16 
In this respect, adaptive rather than innate immunity offers 
the greatest potential for durable, robust anticancer immune 
responses. Of note, some of the cells involved in innate immu-
nity, such as DCs, macrophages, and NK cells, also play a role 
in adaptive immunity.4
The adaptive anticancer immune response is initiated by 
immature DCs, which are found in most human tumors and 
are capable of capturing antigens released from cancer cells 
(Fig. 1).17,18 After maturation (activation), DCs present tumor 
antigens within major histocompatibility complex (MHC) mol-
ecules to naïve T cells in the tumor-draining lymph nodes, trig-
gering a protective T-cell response composed of specific CD4+ 
helper T (Th) cells and CD8+ cytotoxic T cells. T-cell activation 
requires interaction not only between the antigen–MHC com-
plex on DCs and T-cell receptors but also among an array of 
co-stimulatory molecules, including CD80/86 on DCs and the 
CD28 receptor on T cells. After infiltrating the tumor, activated 
cytotoxic T cells are capable of recognizing and killing tumor 
cells directly in an MHC-restricted fashion. In addition, acti-
vated Th cells secrete cytokines that induce inflammation and 
recruit other immune cell populations to the tumor microenvi-
ronment to eliminate cancer cells. DCs may also induce B-cell-
mediated antibody responses and NK cell activity.
Promotion of Tumor Growth 
by the Immune System
Insights into cellular and molecular immunologic pro-
cesses have revealed that the immune system is capable of 
not only inhibiting but also promoting tumor growth, through 
either the selection of tumor cells that are better able to sur-
vive in an immunocompetent host or the creation of condi-
tions within the tumor microenvironment that facilitate tumor 
growth.5,6 It has been proposed that this dual host-protective 
and tumor-promoting role results from a dynamic relationship 
between cancer cells and the immune system termed “immu-
noediting,” which consists of three distinct phases: elimination, 
equilibrium, and escape (Fig. 2).15 In the elimination phase, 
acute immune responses, both innate and adaptive, recognize 
and destroy cancer cells (through a process termed “immuno-
surveillance”) before they develop into a clinically detectable 
tumor.5,6,15 Early evidence suggested that premalignant clones 
expressing novel somatic mutant epitopes (immunogenic por-
tions of antigens) might be targeted by the immune system in 
the initial stages of tumor development.19 Tumor clones that 
escape the elimination phase remain dormant in the subse-
quent equilibrium phase, during which tumor growth does not 
occur but the immunogenicity of the tumor cells continues to 
be shaped by selective immune pressure from the adaptive 
immune response.6,15 In time, changes arising in the tumor cell 
population caused by this selective pressure and/or changes in 
the immune system as a result of prolonged tumor-mediated 
immunosuppression may lead to immune escape and tumor 
growth.6,15
Tumor cells entering the immune escape phase are able to 
create an immunosuppressive state within the tumor microen-
vironment by subverting the same mechanisms that under nor-
mal conditions help regulate the immune response and prevent 
damage to healthy tissue.6 Key immunosuppressive cell types 
found in the tumor microenvironment are regulatory T (T
reg
) 
cells, myeloid-derived suppressor cells (MDSCs), and tumor-
associated macrophages.6,17,20 T
reg
 cells, which are positive for 
CD4, CD25, and the Foxp3 transcription factor, suppress the 
function and proliferation of tumor-specific CD4+ and CD8+ 
T cells and NK cells, whereas MDSCs induce T
reg
 cells and 
limit effector T-cell proliferation by means of the production 
of various immunosuppressive molecules.6,17 Tumor-associated 
macrophages and stromal cells may also secrete cytokines that 
inhibit an adaptive immune response, such as IL-10 and trans-
forming growth factor-β (TGF-β).16,20 In addition, both tumor 
cells and other cells present in the tumor microenvironment 
may express the immunosuppressive enzyme indoleamine-
2,3-dioxygenase, which depletes the amino acid tryptophan 
FIGURE 1.  Adaptive anticancer immunity. The 
adaptive anticancer immune response is initiated by 
immature DCs, which capture and process tumor 
antigens. DCs subsequently undergo maturation 
and migrate to tumor-draining lymph nodes, where 
they present tumor antigens within MHC mol-
ecules to naïve T cells, triggering a protective T-cell 
response. T-cell activation requires interaction not 
only between the antigen–MHC complex on DCs 
and TCRs but also among an array of co-stimulatory 
molecules, including CD80/86 on DCs and the 
CD28 receptor on T cells. The adaptive anticancer 
immune response culminates with the infiltration 
of activated cytotoxic T cells into the tumor, killing 
cancer cells. DC, dendritic cell; MHC, major histo-
compatibility; TCR, T-cell receptor.
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(essential for T-cell function), increases local T
reg
 populations, 
and induces  tumor-specific T-cell deactivation.20
Even if  T cells can otherwise be activated, specific physi-
ologic regulatory mechanisms, or “checkpoints,” which play a 
key role in maintaining normal self-tolerance and limiting the 
extent of immune responses to infection, can be exploited by 
tumors as immune resistance mechanisms.21 Two of the most 
investigated checkpoint receptors in terms of immunothera-
peutic targets for cancer are cytotoxic T-lymphocyte antigen-4 
(CTLA-4) and programmed death-1 (PD-1) receptor, which 
downregulate T-cell activation, proliferation, and function 
through different mechanisms.
CTLA-4 is expressed on the surface of T cells after 
activation and shares the same ligands (CD80/86 expressed 
by APCs) as the co-stimulatory T-cell CD28 receptor, which 
is required for T-cell activation (Fig. 3A).21 By virtue of its 
higher affinity for these ligands, CTLA-4 competes with the 
CD28 receptor in binding to CD80/86, thereby providing an 
inhibitory signal to the T cell and serving as a negative feed-
back loop for T-cell activation. In the cancer setting, inhibiting 
the T-cell response through the CTLA-4 pathway favors tumor 
survival over elimination. CTLA-4 is also constitutively 
expressed by T
reg
 cells and has a critical effect on the ability of 
these cells to regulate antitumor immunity.22
The PD-1 pathway is also an important mechanism 
by which tumors develop immune resistance (Fig. 3B).15,21 
Upregulation of the PD-1 receptor on activated T cells and 
subsequent binding to one of its ligands, programmed death 
ligand-1 (PD-L1) or PD-L2, provide an inhibitory signal 
during the effector phase of the T-cell response, reducing 
FIGURE 2.  Cancer  immunoediting. 
The proposed process of cancer 
immunoediting consists of three 
distinct phases: elimination, equilib-
rium, and escape. In the elimination 
phase, innate and adaptive immune 
responses recognize and destroy 
cancer cells (immunosurveillance), 
suppressing tumor development. 
In the equilibrium phase, tumor 
clones that escape the elimination 
phase remain dormant, during which 
tumor growth does not occur but 
the immunogenicity of the tumor 
cells continues to be shaped by 
selective immune pressure. In the 
escape phase, tumor cell clones that 
are resistant to the immune system 
proliferate unchecked. Adapted with 
permission from Annu Rev Immunol 
2011;29:235–271.
FIGURE 3.  Immune checkpoints. A, Cytotoxic 
CTLA-4 is expressed on T cells after activation and 
competes with the co-stimulatory T-cell CD28 
receptor for CD80/86 expressed by APCs, providing 
an inhibitory signal to the T cell. B, PD-1 receptor is 
upregulated on activated T cells and subsequently 
binds to one of its ligands, PD-L1 or PD-L2, which 
are usually expressed on tumor cells, providing an 
inhibitory signal to the T cell. APC, antigen-present-
ing cell; MHC, major histocompatibility; TCR, T-cell 
receptor; CTLA-4, cytotoxic T-lymphocyte antigen-4; 
PD-L1/L2, programmed death ligand-1/ligand-2; 
PD-1, programmed death-1. Adapted with permis-
sion from Nat Rev Cancer 2012;12:252–264.
Copyright © 2015 by the International Association for the Study of Lung Cancer
977Copyright © 2015 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 7, July 2015 Role of the Immune System in Non–Small-Cell Lung Cancer
cytokine production, cell proliferation, and cell survival sig-
naling. PD-1 is also expressed at high levels on T
reg
 cells, 
enhancing their proliferation in the presence of a PD-1 ligand. 
In addition, PD-1 may be induced on activated NK cells, 
thereby limiting their lytic activity. Present on a wide vari-
ety of hematopoietic and nonhematopoietic cells, PD-L1 and 
PD-L2 are also usually expressed on tumor cells.21,23 Although 
the clinical significance of PD-L1 expression on tumor cells is 
yet to be fully characterized, it is thought to confer a survival 
advantage to the tumor through the PD-1 pathway.17 PD-L1 
tumor cell expression is induced by means of IFN-γ secreted 
by infiltrating Th cells as part of an adaptive immune resis-
tance mechanism.20 Recent evidence shows that the induction 
of tumor PD-L1 expression can also be upregulated by onco-
genic signaling intrinsic to the tumor cells themselves.24
In addition to immunosuppressive mechanisms that 
undermine antitumor immunity, chronic inflammation can 
paradoxically promote tumor growth.25 In fact, chronically 
activated leukocytes produce a range of molecules that can 
directly stimulate tumor growth, including epidermal growth 
factor, TGF-β, and tumor necrosis factor alpha. The develop-
ment of this chronic inflammatory environment also confers a 
survival advantage to tumor cells by increasing the chance of 
DNA damage and accumulation of oncogenic mutations.
ROLE OF THE IMMUNE SYSTEM IN NSCLC
The Immunosuppressive NSCLC 
Tumor Microenvironment
Like other tumor types, NSCLC can establish an immu-
nosuppressive tumor microenvironment conducive to tumor 
growth.12–14 For instance, NSCLC tumors have been shown to 
contain large numbers of T
reg
 cells that constitutively express 
high levels of CTLA-4 on their surface and directly inhibit 
T-cell proliferation.26,27 In addition, in NSCLC, tumor-infil-
trating CD8+ T cells have shown increased PD-1 expression 
that was associated with impaired immune function.28 PD-L1 
expression has also been found to be upregulated on NSCLC 
tumor cells29 and shown to correlate with the suppression of 
maturation of tumor infiltrating DCs30 and reduced tumor 
T-cell infiltration.31 Furthermore, dysfunction of the anti-
gen-presentation apparatus appears to impair immunologic 
activity in the tumor microenvironment, as lung tumor cells 
can downregulate surface expression of MHC class I/tumor 
antigen expression, thereby helping these cells to evade the 
immune system.32 Lung tumor cells may also release immune 
suppressive cytokines, including IL-10 and TGF-β.33
Immune Correlates of Clinical 
Outcome in NSCLC
Further underscoring the involvement of the immune 
system in NSCLC, a number of immune correlates of clinical 
outcome in patients with NSCLC have been identified. One of 
the most remarkable pieces of clinical evidence for immune 
system involvement in NSCLC is the presence of “preformed” 
antitumor T cells and antibodies in the blood of patients 
with NSCLC.34,35 Moreover, tumor-infiltrating lymphocytes 
(TILs), composed mainly of CD8+ T cells, were significantly 
associated with improved survival and correlated with tumor 
grade, size, vascular invasion, and poor levels of differentia-
tion among patients with NSCLC.36 The presence of TILs has 
also been linked with a better survival outcome in NSCLC 
at an early stage as well as a reduced risk of systemic recur-
rence.37 In separate studies, high levels of infiltrating CD8+ 
T cells, both CD8+ and CD4+ T cells, and T cells expressing 
the pan T-cell marker CD3,38–40 as well as higher densities of 
mature DCs in tertiary lymphoid structures,41 have been asso-
ciated with improved survival. Conversely, the number of T
reg
 
cells42,43 and higher numbers of macrophages with protumor 
functions44 in NSCLC tumors have been shown to be inde-
pendent predictors of reduced survival. PD-L1 expression 
on tumor cells also correlates with an unfavorable prognosis 
in patients with NSCLC.23,29,30 Finally, high activity levels 
of nuclear factor kappa-light-chain-enhancer of activated B 
cells, a transcription factor constitutively activated in many 
tumor types, have been associated with the recruitment and 
infiltration of antitumor T cells into tumor tissue and extended 
survival in patients with NSCLC.45
DEVELOPMENT OF IMMUNOTHERAPY  
FOR NSCLC
Given the clear role of the immune system in NSCLC, 
research efforts are being intensively directed toward the 
development of various immunotherapies for the disease, 
particularly those promoting adaptive immune responses.12–14 
Cancer immunotherapy can be broadly divided into antigen-
specific and antigen-nonspecific therapies, with the respective 
aims of stimulating specific antitumor immunity and influenc-
ing steps after the immune system has been previously stimu-
lated. Examples of antigen-specific and antigen-nonspecific 
immunotherapies include cancer vaccines and immune check-
point inhibitors, respectively. A number of immunotherapeutic 
strategies for NSCLC, including those that stimulate immune 
processes and counteract tumor immune evasion, are being 
investigated in clinical trials (Table 1).46–59
Immune Checkpoint Inhibitors
Perhaps the most significant advances in NSCLC immu-
notherapy have been made by targeting immune checkpoint 
pathways to prevent or reduce tumor-mediated immune sup-
pression. In particular, several monoclonal antibodies that 
block immune checkpoint pathways, such as those involving 
PD-1 and CTLA-4, are being investigated in clinical trials 
with NSCLC (Table 2).47–50,52–55 These immune checkpoint 
inhibitors offer the advantage of enhancing the host’s own 
antitumor immune response without regard to the specific 
tumor antigen, thus conferring broader clinical application 
than antigen-specific immunotherapies, such as vaccines.12
Nivolumab (BMS-936558; ONO-4538), a fully human 
immunoglobulin G4 (IgG4) monoclonal antibody directed 
against PD-146,60 that was approved in 2014 in the United 
States61 and Japan62 for treating patients with advanced 
melanoma, is being investigated for advanced NSCLC.47 
Nivolumab was approved in the United States in 2015 for 
treating patients with metastatic squamous NSCLC with pro-
gression on or after platinum-based chemotherapy.63 In a phase 
Copyright © 2015 by the International Association for the Study of Lung Cancer
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I study (Table 2), in previously treated patients with advanced 
NSCLC (n = 129), nivolumab demonstrated an objective 
response rate (ORR) based on Response Evaluation Criteria 
In Solid Tumors (RECIST) v1.0 of 17% across all doses eval-
uated and 24% with 3 mg/kg dose given every 2 weeks (the 
dose selected for phase III studies), with an estimated median 
response duration of 74 weeks both across all doses and at 
the 3 mg/kg dose.47 Across all doses, responses occurred early, 
with 50% of patients demonstrating a response at 8 weeks, 
and were ongoing in 45% of patients. Responses occurred in 
various NSCLC patient subpopulations, including those with 
squamous and nonsquamous cell histology (17% and 18%), 
who received less than three and greater than or equal to three 
prior therapies (12% and 21%), who were less than 70 and 
greater than or equal to 70 years of age (17% and 18%), and 
with and without tumors driven by epidermal growth factor 
receptor (EGFR; 17% and 20%) or Kristen rat sarcoma onco-
gene homolog (KRAS) mutations (14% and 25%). Across all 
doses, median OS was 9.9 months, with 1- and 2-year sur-
vival rates of 42% and 24%, respectively. With the 3 mg/kg 
dose, median OS was 14.9 months, with 1- and 2-year survival 
rates of 56% and 45%, respectively. Although it is difficult 
to compare findings between trials, the survival results with 
nivolumab are promising relative to previous experience with 
approved therapies in treatment-refractory, advanced NSCLC 
populations (median OS, 6–8 months; 1-year survival rate, 
approximately 30%).64–67 Nivolumab had a manageable safety 
profile, with the most common treatment-related adverse 
events (any grade) being fatigue (24%), decreased appetite 
(12%), and diarrhea (10%).47 Grade 3–4 treatment-related 
adverse events occurred in 14% of patients. In another phase 
I study (CheckMate 012; Table 2), nivolumab showed clinical 
activity, with a RECIST v1.1-based ORR of 30%, in chemo-
therapy-naïve patients with advanced NSCLC.48 In addition, 
in the same phase I study (CheckMate 012; Table 2), chemo-
therapy-naïve patients with EGFR-mutant advanced NSCLC 
achieved a RECIST v1.1-based ORR of 19% with nivolumab 
plus erlotinib, an EGFR tyrosine kinase inhibitor.49 Nivolumab 
also demonstrated clinical meaningful activity (RECIST v1.1-
based ORR: 15%) in a phase II, single-arm study (CheckMate 
063; Table 2) with patients having advanced, refractory 
squamous NSCLC (n = 177).50 Phase III trials are evaluat-
ing nivolumab monotherapy versus current standard of care 
as first-line therapy for squamous and nonsquamous NSCLC 
(NCT02041533 [CheckMate 026]) or subsequent line of ther-
apy for nonsquamous NSCLC (NCT01673867 [CheckMate 
057]). A phase III study (NCT01642004 [CheckMate 017]) 
evaluating nivolumab versus docetaxel in patients with stage 
IIIB/IV squamous NSCLC with disease recurrence or pro-
gression during or after one prior platinum doublet-based che-
motherapy regimen was stopped early because an assessment 
conducted by the independent Data Monitoring Committee 
found that the study met its primary end point of superior OS 
with nivolumab.51 It should be noted that some of these phase 
III trials did not select patients for PD-L1 expression and may 
thus provide an opportunity for its validation as a potential 
predictive biomarker.
Pembrolizumab (MK-3475), a humanized IgG4 mono-
clonal antibody directed against PD-1 that was approved in 
2014 in the United States for treating patients with advanced 
or unresectable melanoma who are no longer responding to 
other agents,68 is being assessed for NSCLC.52 In a phase I 
study (KEYNOTE-001; Table 2) with patients with treatment-
naïve and previously treated NSCLC (n = 262), pembroli-
zumab demonstrated a RECIST v1.1-based ORR of 21%.52 
ORR was higher for patients who were treatment-naïve versus 
previously treated (26% and 20%, respectively), had nonsqua-
mous versus squamous histology (23% versus 18%, respec-
tively), were current or former versus never smokers (27% 
versus 9%, respectively), and had tumor with KRAS versus 
EGFR mutations (39% versus 36%, respectively). Median OS 
in the treatment-naïve and previously treated cohorts was not 
TABLE 1.  Immunotherapeutic Agents in Clinical Development for the Treatment of Advanced Non–Small-Cell Lung Cancer
Agent Description
Checkpoint inhibitors
  Nivolumab Fully human IgG4 monoclonal antibody directed against PD-1 on T cells
  Pembrolizumab (MK-3475) Humanized IgG4 monoclonal antibody directed against PD-1 on T cells
  BMS-936559 Fully human IgG4 monoclonal antibody directed against PD-L1 on tumor cells
  MPDL3280A Human IgG1 monoclonal antibody directed against PD-L1 on tumor cells
  MEDI4736 Fully human IgG1 monoclonal antibody directed against PD-L1 on tumor cells
  Ipilimumab Fully human IgG1 monoclonal antibody directed against CTLA-4 on T cells
  Lirilumab (IPH2102) Fully human monoclonal antibody directed against the killer-cell immunoglobulin-like receptor on NK cells
  BMS-986016 Monoclonal antibody directed against the lymphocyte-activation gene 3 on tumor infiltrating lymphocytes
Vaccines
  Tecemotide (liposomal BLP25) Vaccine composed of the exposed core peptide of MUC-1
  Racotumomab Patient idiotype-specific vaccine against NGg GM3
  TG4010 Vaccine that uses a recombinant vaccinia virus (modified virus of Ankara) that encodes for human MUC-1 and IL-2
Nonspecific immune stimulator
  Talactoferrin alfa Recombinant human lactoferrin
CTLA-4, cytotoxic T lymphocyte antigen-4; IgG, immunoglobulin G; IL-2, interleukin-2; MUC-1, mucin 1; NGg, N-glycolil; NK, natural killer; NSCLC, non–small-cell lung 
cancer; PD-1, programmed death-1; PD-L1, programmed death ligand-1.
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reached and 8.2 months, respectively. The most common treat-
ment-related adverse events (any grade) were fatigue (20%), 
pruritus (9%), arthralgia (8%), decreased appetite (8%), and 
diarrhea (7%). Grade 3–4 treatment-related adverse events 
occurred in 9% of patients. A phase II/III study is ongoing 
comparing two dose levels of pembrolizumab with docetaxel 
in pretreated patients with advanced NSCLC (NCT01905657 
[KEYNOTE-010]). Phase III studies comparing first-line 
pembrolizumab monotherapy with platinum-based doublet 
chemotherapy in PD-L1-positive, advanced NSCLC are 
recruiting patients (NCT02142738 [KEYNOTE-024] and 
NCT02220894 [KEYNOTE-042]).
Targeting the PD-1 ligand PD-L1 may provide an alter-
native strategy for NSCLC. In a phase I study (Table 2) with 
patients with squamous or nonsquamous NSCLC (n = 37), 
MPDL3280A, a human IgG1 monoclonal antibody directed 
against with an engineered fragment crystallizable (Fc) 
domain to prevent antibody-dependent cell-mediated cytotox-
icity and complement-dependent cell-mediated cytotoxicity 
of tumor-infiltrating T cells meant to be activated,69 achieved 
an RECIST v1.1-based ORR of 24%.53 ORR was greater in 
the former or current smokers (25%) than in never smokers 
(16%). Grade 3–4 adverse events, regardless of attribution, 
occurred in 34% of patients and included pericardial effusion 
(6%), dehydration (4%), dyspnea (4%), and fatigue (4%). A 
phase II study is currently examining the use of MPDL3280A 
in patients with PDL1-positive advanced NSCLC (FIR 
study [NCT01846416]). Phase II and III studies are also 
underway comparing MPDL3280A with docetaxel among 
patients with advanced NSCLC who failed previous platinum 
therapy (POPLAR study [NCT01903993] and OAK study 
[NCT02008227], respectively).
MEDI4736, a fully human IgG1 monoclonal antibody 
directed against PD-L1 containing an engineered IgG1 Fc 
domain to prevent antibody-dependent cell-mediated cytotox-
icity and complement-dependent cell-mediated cytotoxicity 
of tumor-infiltrating T cells,69 produced a RECIST v1.1-based 
ORR of 16% in a phase I study (Table 2) with patients with 
NSCLC (n = 155), who were mostly pretreated54 and is being 
further studied in phase II/III studies with patients with 
NSCLC (Lung-MAP study [NCT02154490] and ATLANTIC 
study [NCT02087423]).
Research is underway to identify biomarkers that might 
predict which patients respond best to PD-1 pathway inhibi-
tors, the most promising of which may be the level of PD-L1 
expression in the tumor microenvironment. Considering 
the role of PD-L1 in tumor immune evasion, it is logical to 
assume that PD-L1 expression would be a viable biomarker.21 
In preliminary analyses with various PD-1 pathway inhibitors, 
expression of PD-L1 on tumor cells at baseline appeared to 
correlate with increased efficacy.46–48,50,52–54 For example, in the 
phase II CheckMate 063 study with nivolumab in patients hav-
ing advanced, refractory squamous NSCLC, RECIST-based 
ORR was greater in patients with PD-L1-positive tumors (≥5% 
tumor cells expressing PD-L1 by immunohistochemistry 
[IHC]) versus PD-L1-negative tumors (24% [6 of 25] versus 
14% [7 of 51], respectively).50 Similarly, among treatment-
naïve and previously treated patients with advanced NSCLC 
receiving pembrolizumab in the phase I KEYNOTE-001 
trial, ORR by RECIST was greater in patients with PD-L1-
positive tumors (≥1% tumor cells expressing PD-L1 by IHC) 
than in those with PD-L1-negative tumors (23% versus 9%).52 
Patients in that study, who were PD-L1 strong-positive (≥50% 
membranous staining in tumor cells) versus PD-L1 weak-pos-
itive or negative demonstrated longer median OS (hazard ratio 
[HR]: 0.59; 95% confidence interval: 0.35–0.99) and median 
progression-free survival (HR: 0.52; 95% confidence inter-
val: 0.33–0.80). Expression of PD-L1 on tumor-infiltrating 
immune cells may also be predictive of response with anti-PD-
L1 agents, as suggested in a phase 1 study of MPDL3280A 
with NSCLC patients showing that RECIST-based ORRs 
were significantly associated with tumor-infiltrating immune 
cell PD-L1 expression (p = 0.015).70 PD-L1-positive tumor-
infiltrating immune cells included macrophages, DCs, and T 
cells. In that study, responses occurred in 83% of patients (5 of 
6) with an IHC score of three (≥10% of cells per area express-
ing PD-L1) compared with 20% (4 of 20), 15% (2 of 13), 
and 14% (1 of 7) of patients with IHC scores of zero (<1% of 
cells), one (≥1% but <5% of cells), and two (≥5% but <10% 
of cells), respectively. The conclusions that can be drawn from 
these analyses, however, are limited by several factors, includ-
ing small patient numbers due to low rate of tissue sample 
ascertainment, the use of archival (versus fresh) tumor sam-
ples, use of ORR (which may not be the optimal end point 
to assess the predictive role of biomarkers for immune-based 
therapies), the dynamic nature of and intratumor variations 
in PD-L1 expression, the effect of prior treatment on PD-L1 
status, lack of standardization of IHC assays, and undefined 
cutoff values for PD-L1 positivity.23,47,50 The use of PD-L1 
as a biomarker is therefore being further explored in larger 
NSCLC trials.
The fully human IgG1 monoclonal antibody ipilim-
umab, which is directed against CTLA-4, has shown anti-
tumor activity and a survival advantage with advanced 
melanoma9 and may have potential in treating patients with 
advanced NSCLC.55 A phase II study (Table 2) compared 
ipilimumab plus paclitaxel and carboplatin (concurrent or 
phased administration) with paclitaxel and carboplatin alone 
(control) in chemotherapy-naïve patients with stage IIIB/
IV NSCLC (n = 204).55 In that study, phased administration 
(paclitaxel and carboplatin followed by ipilimumab plus pacli-
atxel and carboplatin) demonstrated significantly improved 
median immune-related progression-free survival (irPFS), the 
primary study end point, compared with paclitaxel and car-
boplatin alone (5.7 versus 4.6 months; HR: 0.72; p = 0.05), 
with greater improvements in irPFS occurring with squa-
mous versus nonsquamous histology. However, concurrent 
administration (ipilimumab plus paclitaxel and carboplatin 
followed by paclitaxel and carboplatin) did not significantly 
improve irPFS versus control. There was a nonstatistical trend 
toward improved median OS with phased administration com-
pared with control, but not with concurrent administration. 
Ipilimumab did not seem to impact toxicities associated with 
paclitaxel and carboplatin. Immune-mediated adverse events 
(e.g., rash, pruritus, diarrhea) occurred more frequently in the 
ipilimumab arms than in the control arm. The combination of 
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ipilimumab with paclitaxel and carboplatin is being further 
investigated in a phase III study in patients with stage III/IV 
recurrent squamous NSCLC (NCT01285609).
Interestingly, early results of ipilimumab in combina-
tion with nivolumab in melanoma suggest that a two-pronged 
approach may provide clinical benefit based on the appar-
ently complementary roles of CTLA-4 and PD-1 in negative 
immune regulation.71 A phase I study is also ongoing to evalu-
ate this combination in treatment-naïve advanced patients 
with NSCLC (NCT01454102). In addition, MEDI4736 com-
bined with tremelimumab, an IgG2 anti-CTLA-4 antibody, is 
being investigated in patients with previously treated NSCLC 
in a phase I study (NCT02000947).72
Overall, immune checkpoint inhibitors that target the 
PD-1 or CTLA-4 pathways have manageable safety profiles 
(Table 2).46–50,52–55 These agents are characteristically associ-
ated with immune-related adverse events (e.g., rash, pruritus, 
diarrhea, hypothyroidism, hepatitis), which are consistent 
with the their mechanism of action and can often be managed 
with protocol-specified guidelines (e.g., close patient follow-
up and early administration of systemic corticosteroids and/or 
other immunosuppressive agents).23,47,55,69
Agents that inhibit other immune checkpoint path-
ways may also have potential in treating patients with 
advanced NSCLC.73 For example, lirilumab (IPH2102), 
a fully human IgG4 monoclonal antibody that blocks the 
interaction between killer-cell immunoglobulin-like recep-
tors on NK cells with their ligands,73,74 is being assessed in 
combination with nivolumab (NCT01714739) or ipilim-
umab (NCT01750580) in phase I studies with patients with 
NSCLC. In addition, BMS-986016, a monoclonal antibody 
that binds to lymphocyte-activation gene 3, a CD4-related 
immune checkpoint receptor co-expressed with PD-1 on 
tolerant TILs,74 is being evaluated in combination with 
nivolumab in patients with advanced solid tumors in a phase 
1 study (NCT01968109).
Although durable clinical responses have been docu-
mented in patients with various tumor types treated with 
immune checkpoint inhibitors, the genetic basis for these 
benefits is only beginning to be understood. Recent research 
suggests that patients more likely to achieve meaningful 
responses to CTLA-4 inhibition have tumors displaying 
neoantigens, which result from specific somatic mutations 
harbored by the tumor and elicit an antitumor response 
augmented by CTLA-4 inhibition.75 Such tumor antigens 
could be immunogenic and potentially function as targets 
of T cells activated by immune checkpoint inhibition.76,77 
Therefore, methods are being developed for predicting 
immunogenic tumor mutations, thereby identifying patients 
who would best benefit from immune checkpoint inhibitors 
and allowing personalized treatment.77
Cancer Vaccines
Cancer vaccines aim to stimulate the immune system 
to recognize and respond to one or more tumor antigens, 
which ideally show exclusive or elevated expression on 
cancer cells.12 However, as most tumor antigens are closely 
related or identical to self-antigens and therefore weakly 
antigenic, cancer vaccines usually incorporate strong adju-
vants to stimulate efficient DC presentation of these pro-
teins.17 A number of cancer vaccines are currently in clinical 
trials in NSCLC, including tecemotide (liposomal BLP25),56 
racotumomab,57 and TG4010,58 which have shown a range 
of responses and survival outcomes (reviewed in detail 
elsewhere).12–14 Current evidence suggests that, despite the 
potential for inducing long-lasting immune memory, vac-
cine therapy may be most effective in patients with a lower 
disease burden.13
Nonspecific Immune Stimulation
Nonspecific immune stimulation has been investigated 
therapeutically in different cancers, including NSCLC.12 
One agent recently evaluated in NSCLC is talactoferrin 
alfa, a recombinant form of human lactoferrin and an oral 
DC-mediated immunotherapy that stimulates cytokine release 
in the intestine, with subsequent recruitment and activation of 
DCs. However, talactoferrin alfa did not lead to improved OS 
versus placebo in a phase III study in patients with advanced, 
pretreated NSCLC.59
CONCLUSIONS
Although traditionally considered a nonimmunogenic 
disease, NSCLC is now recognized to elicit an endogenous 
immune response. Emerging results with a range of immu-
notherapeutic agents, such as immune checkpoint inhibitors 
indicate that this therapeutic modality could eventually have 
a significant impact upon the survival and quality of life of 
patients with NSCLC, for whom the outlook is currently 
bleak. Further investigation into the dysregulation of the 
immune system induced by tumor cells during development 
of NSCLC and additional results from ongoing studies will 
provide insight on how immunotherapy can be used to shift 
the balance of immune control away from a tumor-induced 
immune suppressive state to an active antitumor immune 
response.
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